Biosimilars for Humira are drugs that are similar to the biologic drug Humira, which is used to treat a variety of autoimmune diseases. Biosimilars are designed to have the same efficacy and safety as the original biologic drug. Humira is a brand name for adalimumab, which is a biologic drug that works by blocking the activity of tumor necrosis factor-alpha (TNF-alpha), a protein that contributes to inflammation in the body. Biosimilars for Humira are developed using a complex process that involves comparing the biosimilar to the original biologic drug in terms of quality, safety, and efficacy.

Amjevita (adalimumab-atto) is the first biosimilar to Humira that was approved by the FDA in 2016 [2]. It is manufactured by Amgen and was launched in the United States in 2023 [2]. Amjevita has been shown to have similar efficacy and safety as Humira in clinical trials [2]. Other biosimilars for Humira that have been approved by the FDA include Cyltezo (adalimumab-adbm) and Hyrimoz (adalimumab-adaz) [3].

Biosimilars for Humira are expected to provide more affordable options for patients with autoimmune diseases, as they are generally less expensive than the original biologic drug [3]. GoodRx reports that the average retail price for a 40 mg/0.8 mL syringe of Humira is $6,690, while the average retail price for a 40 mg/0.8 mL syringe of Amjevita is $4,342 [3]. However, it is important to note that the actual cost of biosimilars may vary depending on factors such as insurance coverage and discounts offered by the manufacturer [3].

Overall, biosimilars for Humira are drugs that are designed to be similar to the original biologic drug in terms of quality, safety, and efficacy. They are expected to provide more affordable options for patients with autoimmune diseases. Amjevita is the first biosimilar to Humira that was approved by the FDA and is now available in the United States.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/HUMIRA
[2] https://www.amgen.com/newsroom/press-releases/2023/01/amjevita-adalimumabatto-first-biosimilar-to-humira-now-available-in-the-united-states
[3] https://www.goodrx.com/humira/biosimilars